Hertraz Injection

✅ Targets HER2-positive tumors
✅ Inhibits cancer cell growth
✅ Reduces tumor recurrence
✅ Enhances survival rates
✅ Improves treatment outcomes

Hertraz Injection contains Trastuzumab.

Product Overview

Hertraz Injection is a medication containing the active ingredient Trastuzumab, available in vial form with a concentration of 440mg per vial. Trastuzumab is a monoclonal antibody used in the treatment of certain types of cancer, including breast cancer and gastric cancer. It is a targeted therapy that works by binding to specific receptors on cancer cells, inhibiting their growth and promoting cell death. Hertraz Injection is administered intravenously under the supervision of a healthcare professional.


Hertraz Injection is indicated for the treatment of HER2-positive breast cancer, either alone or in combination with other chemotherapy agents. It is also used in combination with other drugs to treat HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. HER2-positive cancers overexpress the human epidermal growth factor receptor 2 (HER2), and Trastuzumab specifically targets these receptors to inhibit cancer cell proliferation.

How to Use

Hertraz Injection is administered as an intravenous infusion by a healthcare provider in a clinical setting. The dosage and infusion rate are determined based on the patient’s body weight and medical condition. Prior to administration, the vial should be inspected visually for any particulate matter or discoloration. The injection should be given over a specified period, and patients are monitored for any signs of infusion-related reactions during and after the infusion.

How it Works

Trastuzumab, the active ingredient in Hertraz Injection, is a monoclonal antibody that targets and binds to the HER2 receptors present on the surface of cancer cells. By binding to these receptors, Trastuzumab inhibits downstream signaling pathways that promote cell proliferation and survival. Additionally, it can stimulate the immune system to attack HER2-positive cancer cells, further enhancing its anticancer effects. This targeted approach helps to selectively destroy cancer cells while minimizing damage to healthy tissues.

Dosage and Administration

The recommended dosage of Hertraz Injection varies depending on the type and stage of cancer being treated, as well as other factors such as the patient’s weight and overall health. It is typically administered intravenously every 1 to 3 weeks, with the dosage adjusted based on the patient’s tolerance and response to treatment. Treatment duration may vary, and patients should follow the dosing schedule recommended by their healthcare provider.


  • Effective in the treatment of HER2-positive breast cancer and gastric cancer
  • Targeted therapy with minimal impact on healthy cells
  • Can be used alone or in combination with other chemotherapy agents
  • May improve overall survival and reduce the risk of cancer recurrence
  • Well-tolerated with manageable side effects compared to traditional chemotherapy

Common Side Effects

Common side effects of Hertraz Injection may include infusion-related reactions, such as fever, chills, nausea, vomiting, headache, fatigue, and allergic reactions. Some patients may experience cardiotoxicity, manifested as decreased heart function or heart failure, and monitoring of cardiac function is recommended during treatment.


Patients receiving Hertraz Injection should be monitored closely for signs of cardiac toxicity, particularly those with pre-existing heart conditions or a history of cardiac dysfunction. The medication should be used with caution in pregnant or breastfeeding women, as it may harm the developing fetus or nursing infant. Prior to initiation of treatment, patients should undergo thorough cardiac evaluation, and concomitant use with anthracycline-based chemotherapy should be avoided due to increased risk of cardiotoxicity.

Storage Information

Hertraz Injection should be stored in its original packaging at controlled room temperature, away from light and moisture. The vials should be protected from freezing and kept out of the reach of children and pets. Unused portions of the medication should be discarded properly according to local regulations.


Our sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover all possible side effects, drug interactions or warnings or alerts. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.


440 mg


1 Vial/s, 2 Vial/s, 3 Vial/s, 6 Vial/s


There are no reviews yet.

Be the first to review “Hertraz Injection”